Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272

Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, ESC Scientific Document Group (2018) 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 39(9):763–816. https://doi.org/10.1093/eurheartj/ehx095 (Endorsed by: the European Stroke Organization (ESO),The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 135(12):e686–e725. https://doi.org/10.1161/CIR.0000000000000470

Lawall H, Huppert P, Espinola-Klein C, Zemmrich CS, Ruemenapf G (2017) German guideline on the diagnosis and treatment of peripheral artery disease—a comprehensive update 2016. Vasa 46(2):79–86. https://doi.org/10.1024/0301-1526/a000603

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K, TASC II Working Group (2007) Inter-society consensus for the management of peripheral rterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl 1):S1–S75

Kelly E, Hemphill L (2017) Lipoprotein(a): A lipoprotein whose time has come. Curr Treat Options Cardiovasc Med 19(7):48. https://doi.org/10.1007/s11936-017-0549-z

Zeymer U, Parhofer KG, Pittrow D, Binz C, Schwertfeger M, Limbourg T, Röther J (2009) Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol 98(4):249–256. https://doi.org/10.1007/s00392-009-0754-1

Pereg D, Elis A, Neuman Y, Mosseri M, Segev D, Granek-Catarivas M, Lishner M, Hermoni D (2014) Comparison of mortality in patients with coronary or peripheral artery disease following the first vascular intervention. Coron Artery Dis 25(1):79–82. https://doi.org/10.1097/MCA.0000000000000044

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2018) Low-density lipoprotein cholesterol lowering with Evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 137(4):338–350. https://doi.org/10.1161/CIRCULATIONAHA.117.032235

Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS (2016) Ticagrelor for prevention of Ischemic Eventas after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 67(23):2719–2728. https://doi.org/10.1016/j.jacc.2016.03.524

Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, Kronenberg F, Mueller T (2007) Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem 53(7):1298–1305 (Jul)

Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantner B, Stadler M, Peters A, Koenig W, Stöckl A, Dähnhardt D, Böger CA, Krämer BK, Fraedrich G, Strauch K, Kronenberg F (2014) Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 103(1):28–36. https://doi.org/10.1093/cvr/cvu107

Bérard AM, Bedel A, Le Trequesser R, Freyburger G, Nurden A, Colomer S, Guérin V, Vergnes MC, Becker F, Camelot G, Bressolette L, Lacroix P, Cambou JP, Bura-Rivière A, Emmerich J, Darmon M, Deletraz AM, Mesli S, Colombies B, Vanbrugghe V, Conri C, Constans J (2013) Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study. PLoS ONE 8(3):e37882. https://doi.org/10.1371/journal.pone.0037882

Forbang NI, Criqui MH, Allison MA, Ix JH, Steffen BT, Cushman M, Tsai MY (2016) Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis. J Vasc Surg 63(2):453–458. https://doi.org/10.1016/j.jvs.2015.08.114

Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS (2012) Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 32(12):3058–3065. https://doi.org/10.1161/ATVBAHA.112.255521

Tunstall-Pedoe H, Peters SAE, Woodward M, Struthers AD, Belch JJF (2017) Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC). J Am Heart Assoc 6(9):e5967. https://doi.org/10.1161/JAHA.117.005967

Volpato S, Vigna GB, McDermott MM, Cavalieri M, Maraldi C, Lauretani F, Bandinelli S, Zuliani G, Guralnik JM, Fellin R, Ferrucci L (2010) Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). Am J Cardiol 105(12):1825–1830. https://doi.org/10.1016/j.amjcard.2010.01.370

Sanchez Muñoz-Torrero JF, Rico-Martín S, Álvarez LR, Aguilar E, Alcalá JN, Monreal M, FRENA Investigators (2018) Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis 276:10–14. https://doi.org/10.1016/j.atherosclerosis.2018.07.001

Tsimikas S (2018) RNA-targeted therapeutics for lipid disorders. Curr Opin Lipidol 29(6):459–466. https://doi.org/10.1097/MOL.0000000000000549

Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D, Group of Clinical Investigators (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6(3):229–239. https://doi.org/10.1038/ncpcardio1456

Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128(24):2567–2576. https://doi.org/10.1161/CIRCULATIONAHA.113.002432

Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, Pro(a)LiFe-Study Group (2016) Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol 36(9):2019–2027. https://doi.org/10.1161/ATVBAHA.116.307983

Schatz U, Tselmin S, Müller G, Julius U, Hohenstein B, Fischer S, Bornstein SR (2017) Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels—a multicenter observational study. Atheroscler Suppl 30:246–252. https://doi.org/10.1016/j.atherosclerosissup.2017.05.047

Schampera S, Fischer S, Weiss N, Julius U (2015) Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment. Atheroscler Suppl 18:209–214. https://doi.org/10.1016/j.atherosclerosissup.2015.02.031

Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R (2015) Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl 18:154–162. https://doi.org/10.1016/j.atherosclerosissup.2015.02.013

Poller WC, Dreger H, Morgera S, Berger A, Flessenkämper I, Enke-Melzer K (2015) Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a). Atheroscler Suppl 18:187–193. https://doi.org/10.1016/j.atherosclerosissup.2015.02.032

Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K (2017) Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2‑year follow-up of a prospective single center study. Atheroscler Suppl 30:174–179. https://doi.org/10.1016/j.atherosclerosissup.2017.05.007

Julius U (2017) Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis 5(2):E27. https://doi.org/10.3390/jcdd5020027

Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W (2017) Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. Atheroscler Suppl30:180–186. https://doi.org/10.1016/j.atherosclerosissup.2017.05.009